We also showed that in an in vitro AD model produced by Aβ1–42, Hesperidin pre-treatment significantly increased ADAM10 gene expression, decreased BACE1 gene expression, and consequently reduced Aβ1–42 peptide and phospho-Tau (T181) levels. This evidence concerns the gene ADAM10 and Alzheimer disease.